Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease
Open Access
- 1 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 143 (12) , 3793-3804
Abstract
Neurofilament light (NfL) is a marker of neuroaxonal injury, a prominent feature of Alzheimer’s disease. It remains uncertain, however, how it relates to amyloid and tau pathology or neurodegeneration across the Alzheimer’s disease continuum. The aim of this study was to investigate how plasma NfL relates to amyloid and tau PET and MRI measures of brain atrophy in participants with and without cognitive impairment. We retrospectively examined the association between plasma NfL and MRI measures of grey/white matter volumes in the Alzheimer’s Disease Neuroimaging Initiative [ADNI: n = 1149; 382 cognitively unimpaired control subjects and 767 cognitively impaired participants (mild cognitive impairment n = 420, Alzheimer’s disease dementia n = 347)]. Longitudinal plasma NfL was measured using single molecule array (Simoa) technology. Cross-sectional associations between plasma NfL and PET amyloid and tau measures were independently assessed in two cohorts: ADNI [n = 198; 110 cognitively unimpaired, 88 cognitively impaired (MCI n = 67, Alzheimer’s disease dementia n = 21), data accessed October 2018]; and Translational Biomarkers in Aging and Dementia [TRIAD, n = 116; 74 cognitively unimpaired, 42 cognitively impaired (MCI n = 16, Alzheimer’s disease dementia n = 26), data obtained November 2017 to January 2019]. Associations between plasma NfL and imaging-derived measures were examined voxel-wise using linear regression (cross-sectional) and linear mixed effect models (longitudinal). Cross-sectional analyses in both cohorts showed that plasma NfL was associated with PET findings in brain regions typically affected by Alzheimer’s disease; associations were specific to amyloid PET in cognitively unimpaired and tau PET in cognitively impaired (P < 0.05). Longitudinal analyses showed that NfL levels were associated with grey/white matter volume loss; grey matter atrophy in cognitively unimpaired was specific to APOE ε4 carriers (P < 0.05). These findings suggest that plasma NfL increases in response to amyloid-related neuronal injury in preclinical stages of Alzheimer’s disease, but is related to tau-mediated neurodegeneration in symptomatic patients. As such, plasma NfL may a useful measure to monitor effects in disease-modifying drug trials.Keywords
Funding Information
- Alzheimer's Disease Neuroimaging Initiative
- National Institutes of Health (U01 AG024904)
- DOD ADNI
- Department of Defense (W81XWH-12-2-0012)
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- AbbVie
- Alzheimer’s Association
- Alzheimer’s Drug Discovery Foundation; Araclon Biotech
- BioClinica, Inc.
- Northern California Institute for Research and Education
- University of Southern California
- University of Southern California
- Canadian Institutes of Health Research (MOP-11-51-31)
- Alzheimer’s Association (NIRG-08-92090)
- Canadian Consortium of Neurodegeneration in Aging
- Weston Brain Institute
- Capes Foundation - Brazil (0327/13-1)
- Wallenberg Centre for Molecular and Translational Medicine
- Torsten Söderberg Foundation
- Swedish Research Council (#2017-00915)
- swedish alzheimer foundation (#AF-742881)
- Hjärnfonden, Sweden (#FO2017-0243, #ALFGBG-715986)
- Swedish Research Council (#2018-02532)
- European Research Council (#681712)
- Swedish State Support for Clinical Research (#ALFGBG-720931)
- UK Dementia Research Institute
- Weston Brain Institute
- Canadian Institutes of Health Research
- Canadian Consortium on Neurodegeneration in Aging
- Fonds de Recherche du Québec – Santé (2020-VICO-279314)
- CIHR-CCNA Canadian Consortium of Neurodegeneration in Aging
- Canada Foundation for Innovation
- CIHR Canadian Consortium of Neurodegeneration in Aging
This publication has 40 references indexed in Scilit:
- Soluble amyloid beta levels are elevated in the white matter of Alzheimer’s patients, independent of cortical plaque severityActa Neuropathologica Communications, 2014
- Brain β-amyloid load approaches a plateauNeurology, 2013
- Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersThe Lancet Neurology, 2013
- CSF T-Tau/Aβ42 Predicts White Matter Microstructure in Healthy Adults at Risk for Alzheimer’s DiseasePLOS ONE, 2012
- White matter pathology isolates the hippocampal formation in Alzheimer's diseaseNeurobiology of Aging, 2010
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's diseaseProceedings of the National Academy of Sciences, 2009
- Tau-mediated neurodegeneration in Alzheimer's disease and related disordersNature Reviews Neuroscience, 2007
- Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase–ceramide pathwayJournal of Cell Biology, 2004
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984